You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

WeNatal introduces Iron+ iron and vitamin C supplement

FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer

XtalPi partners with leading biopharma to develop oral small molecule therapeutics for GPCR target

GlycoNex reports positive Phase III trial results for Denosumab biosimilar SPD8

Orionis Biosciences and Novartis form collaboration to advance molecular glue drug discovery

Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP

GMJ Technologies names new CEO

Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial

Antengene granted IND approval in China for ATG-201 in autoimmune disease

FDA grants rare paediatric disease designation to RedHill's opaganib

GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio

Adcentrx Therapeutics' ADRX-0405 granted Chinese regulatory IND clearance to treat late-stage solid tumours

Argo Biopharma to present updated BW-20805 Phase II results at EAACI 2026 Congress

Curasight reports encouraging preliminary Phase 1 data for uTREAT in glioblastoma

Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026